NetworkNewsBreaks – Pressure BioSciences Inc.’
Post# of 1354
(Total Views: 235)
Posted On: 10/15/2020 3:40:01 PM
NetworkNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Path to Commercialization Targets Multibillion Hemp-Derived CBD Market
Pressure BioSciences (OTCQB: PBIO), a developer of innovative solutions for the worldwide life science and other industries, recently achieved another milestone as it nears initial production of commercial systems expected to revolutionize the nanoemulsification process for a wide variety of sectors. The company’s proprietary, next-generation Ultra Shear Technology-based BaroShear K45 System is designed to create unique, high-quality nanoemulsions of otherwise poorly soluble oils in order to render them more easily absorbed and effective in the water-based biology of human bodies. Pressure BioSciences earlier this year announced the launch of its UST Demonstration Laboratory as a place to showcase the technology’s potential to process cannabidiol (“CBD”) oil into true, high-quality, water-soluble nanoemulsions. PBIO reached sold-out status for its initial rollout of 12 planned BaroShear K45 systems. Then, on Oct. 6, the company announced the lock-in of final design specifications for the BaroShear K45’s commercial production model, which immediately launched work on construction of the initial K45 Alpha unit. Upon final completion, testing and approval of the Alpha unit, PBIO will build an additional 14 units, 12 of which are earmarked as ready-for-sale systems in time for the company to fulfill plans for shipping them during early 2021. An article discussing this quotes Pressure BioSciences’ director of marketing and sales, Kenneth F. Micciche. “Our commercialization plan for the BaroShear K45 system is initially focused on the rapidly growing hemp-derived CBD market, which is projected to reach $20 billion by 2020,” Micciche stated in a recent update. “We plan to install these (12 BaroShear K45 nanoemulsification) systems during the first half of 2021, which we believe will generate up to $3 million in revenue. Once these initial units are installed and in commercial use, we believe they will propel the close of multiple sales of additional BaroShear K45 systems during the latter half of 2021 and thereafter.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a developer of innovative solutions for the worldwide life science and other industries, recently achieved another milestone as it nears initial production of commercial systems expected to revolutionize the nanoemulsification process for a wide variety of sectors. The company’s proprietary, next-generation Ultra Shear Technology-based BaroShear K45 System is designed to create unique, high-quality nanoemulsions of otherwise poorly soluble oils in order to render them more easily absorbed and effective in the water-based biology of human bodies. Pressure BioSciences earlier this year announced the launch of its UST Demonstration Laboratory as a place to showcase the technology’s potential to process cannabidiol (“CBD”) oil into true, high-quality, water-soluble nanoemulsions. PBIO reached sold-out status for its initial rollout of 12 planned BaroShear K45 systems. Then, on Oct. 6, the company announced the lock-in of final design specifications for the BaroShear K45’s commercial production model, which immediately launched work on construction of the initial K45 Alpha unit. Upon final completion, testing and approval of the Alpha unit, PBIO will build an additional 14 units, 12 of which are earmarked as ready-for-sale systems in time for the company to fulfill plans for shipping them during early 2021. An article discussing this quotes Pressure BioSciences’ director of marketing and sales, Kenneth F. Micciche. “Our commercialization plan for the BaroShear K45 system is initially focused on the rapidly growing hemp-derived CBD market, which is projected to reach $20 billion by 2020,” Micciche stated in a recent update. “We plan to install these (12 BaroShear K45 nanoemulsification) systems during the first half of 2021, which we believe will generate up to $3 million in revenue. Once these initial units are installed and in commercial use, we believe they will propel the close of multiple sales of additional BaroShear K45 systems during the latter half of 2021 and thereafter.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼